EPAD - European Prevention of Alzheimer's Dementia

European Prevention of Alzheimer's Dementia

- Newsletter May 2020 -

---

Welcome

Dear Friends and Colleagues,

I hope that all of you are safe and healthy in these challenging COVID-19 times. In much the same way as COVID-19 affects our daily lives it also affects EPAD. Most, if not all EPAD research and clinical trial activities had to stop as of early March as progressively Universities across Europe closed, and our clinical sites were either closed or saw site staff redeployed to help fight this pandemic. As previously announced, the annual EPAD General Assembly meeting, which was supposed to take place later this month in Edinburgh, has been cancelled. All this happening at a time when we were preparing EPAD for the post-IMI period, with final reporting and executing on our sustainability plans in full swing. Because of this, Craig and I have engaged IMI to explore the possibility to extend the EPAD project beyond its current end date of 30 June 2020 with 4 months until 31 October 2020. We will keep you abreast of our progress on this front.

Fortunately, all is not gloom and doom. Firstly, two EPAD fellows, Lucy Stirland and Lisa Vermunt, recently earned their PhD – CONGRATULATIONS to both. You can read more about their EPAD journey and their exciting work in this newsletter. Secondly, we are progressing the EPAD 5-component sustainability model that was introduced in the November 2019 newsletter. Unfortunately, also here COVID-19 is causing some delays and set-backs, but the EPAD change management team remains fully engaged in their commitment to execute on our sustainability plans. Although we have been unsuccessful at this time to secure funding that would allow continuation of the EPAD Longitudinal Cohort Study (LCS) as a pan-European cohort, under Craig’s leadership, efforts are underway to redesign the LCS so it can continue at a regional and/or country level. In addition, negotiations are progressing to assure the existing LCS database and data sharing capabilities as well as EPAD’s one of a kind bioresource are maintained and remain accessible for future research. Also at the level of the site network exciting things are happening with EPAD and GAP deciding to join efforts and create a transatlantic site network that will be able to run all manner of clinical trials aimed at finding treatments as well as alleviating symptoms of Alzheimer’s disease. Although also here COVID-19 is causing some delays, we are hopeful that the first of such trials might still be able to start late 2020 or early 2021.

At some point in the hopefully not too distant future COVID-19 will be defeated and we will be able to return to our normal lives. As soon as that happens, we want to make sure EPAD is prepared to pick up where we left it in early March and continue our fight to find a treatment for Alzheimer’s disease. Despite how horrible COVID-19 is, it will pass, while Alzheimer’s disease will still affect millions of lives worldwide. Circumstances may have forced us to hit the pause button in our fight against Alzheimer’s disease just now but our commitment to patients everywhere stays as strong as ever. In the meantime, stay healthy and stay safe.

This electronic newsletter will be published quarterly and be accessible via the EPAD website (http://ep-ad.org/) and inform the Alzheimer’s community on EPAD’s main achievements, upcoming events as well as allow you to meet the scientists who make it all happen.

We hope you enjoy this issue of the EPAD newsletter! Happy Reading!

Serge Van Der Geyten

EPAD Coordinator

---
Message from the EPAD Coordinators to all involved in the EPAD Longitudinal Cohort Study

Highlights Q1 2020

Message from the EPAD Coordinators to all involved in the EPAD Longitudinal Cohort Study

A message from the EPAD Coordinators to all involved in the EPAD Longitudinal Cohort Study  By now you will all be aware of the unexpected closure of the EPAD Longitudinal Cohort Study. We are writing to you to explain the background to this and also to thank you for your commitment to this research and the fight to understand Alzheimer’s disease …

Read more.

---
Two EPAD Fellows successfully defended their PhD thesis

The Story behind the Picture

Two EPAD Fellows successfully defended their PhD thesis

The EPAD consortium wishes to congratulate Lisa Vermunt and Lucy Stirland, two EPAD fellows, on successfully defending their PhD thesis in March 2020. It was two great days and we are proud of their contributions and all the hard work that Lisa and Lucy have put in – very well deserved! We wish them both the best in their future …

Read more.

---

Meet the EPAD team

Interview with Jean Manson

Interview with Jean Manson

What is your current role in EPAD? My current role in EPAD is the PI of the EPAD Bioresource. This is the sample collection that has been taken from EPAD participants from across Europe and is held at the University of Edinburgh. The Bioresource is responsible for the safe storage of these samples and for sending these samples out for …

Read more.

Interview with Rodrigo Barnes

Tell us a bit about the institution/company/organisations you work for. For the last twelve years, I've been working at Aridhia (https://aridhia.com), an SME based in Edinburgh and Glasgow specialising in informatics for biomedical research. After working for some years with specialist clinicians in hospitals and clinics with specialised medical data, we found our current focus at the intersection of clinics, …

Read more.

---

COVID-19 Update and online resource

The worldwide COVID-19 pandemic has inevitably impacted EPAD and its consortium members. The EPAD project management team is monitoring the situation closely. Most EPAD research and clinical trial activities had to stop as of early March as progressively universities across Europe closed, and the clinical sites were either closed or saw site staff redeployed to help fight this pandemic. COVID-19: …

Read more.

---

Quarterly Quote

“Tell me and I forget. Teach me and I remember. Involve me and I learn.”

- Benjamin Franklin -

---